{"slug":"thymosin-alpha-1-biologics","verification":{"valid":true,"entries":23,"head":"3fc46b3307d4cb9e0435a7f629d0b2a0dd99a0c6dfdc2c52f9db83401248e583"},"energy":{"passes":23,"tokens_in":3106,"tokens_out":470,"tokens_total":3576,"cost_usd":0,"models":{"grok/grok-4.3":1,"grok-4.3":10,"system/audit-repair":8,"kimi/moonshot-v1-8k":1,"repair":1,"fill-slots":1,"owner":1},"head":"3fc46b3307d4cb9e0435a7f629d0b2a0dd99a0c6dfdc2c52f9db83401248e583"},"provenance":[{"ts":"2026-06-29T09:28:09.364Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: Thymosin Alpha-1 and Biologic Therapies\n\nAudience: 5M+ on biologics. The problem: biologics suppress immune pathways, leaving patients immunocompromised. Why TA1 maps: studied for immune modulation — supporting immune function without triggering autoimmune response. Novelty: 8/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"thymosin-alpha-1-and-biologic-therapies\",\n  \"title\": \"Thymosin Alpha-1 and Biologic Therapies\",\n  \"body\": \"## Biologics and Immune Suppression\\n\\nBiologic therapies commonly target specific immune pathways, which can result in broad immunosuppression as a side effect.\\n\\n## Thymosin Alpha-1 Overview\\n\\nThymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from the thymus. Human clinical trials have examined its role in immune modulation across multiple conditions.\\n\\n## Human Clinical Data on Immune Modulation\\n\\nA 2024 narrative review of clinical studies involving over 11,000 human subjects across more than 30 trials described Tα1 as a well-tolerated immune modulator (human tier). A 2020 comprehensive literature review summarized its use in conditions including viral hepatitis, HIV, and malignancies, noting effects on restoring or enhancing aspects of immune function (human tier).\\n\\nMultiple systematic reviews and meta-analyses of randomized trials in sepsis and COVID-19 reported changes in immune cell markers such as increased CD4+ T cells or HLA-DR expression alongside reduced mortality in some pooled analyses (human tier).\\n\\n## Preclinical Context\\n\\nEarly isolation of Tα1 occurred in thymectomized mouse models, where it restored immune function (preclinical tier).\\n\\n## Repair-vs-Suppression Framing\\n\\nBiologic agents often act via targeted pathway inhibition. Human trial data on Tα1 have instead documented context-dependent effects on immune cell subsets and responses without uniform suppression (human tier).\\n\\n## Limitations of Available Evidence\\n\\nNo human trials directly compare Tα1 to specific biologic therapies. Most data derive from adjunctive use in infectious or oncologic settings. Where human data are absent for direct biologic comparisons, evidence remains limited to mechanistic descriptions or preclinical models.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"Biologic therapies commonly ta","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"c7ceac19cc5eaea9505ddfb42fef2fdcf5de40365d5e17a59de972d40eb6a7b8"},{"ts":"2026-06-29T11:34:16.415Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c7ceac19cc5eaea9505ddfb42fef2fdcf5de40365d5e17a59de972d40eb6a7b8","hash":"9a87354690b8016f7facdcc7a0b4536dd6b511cf16f7ff983d13d10d32466813"},{"ts":"2026-06-29T12:49:25.761Z","model":"system/audit-repair","action":"repair","prompt":"","input":"thymosin-alpha-1-biologics","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a87354690b8016f7facdcc7a0b4536dd6b511cf16f7ff983d13d10d32466813","hash":"7a21453b9cd430e6f970e8b75021034779c9645c8ff45f8ac22833c44a04c8a2"},{"ts":"2026-06-29T12:49:26.351Z","model":"system/audit-repair","action":"claim","prompt":"","input":"thymosin-alpha-1-biologics c13","response":"Thymosin Alpha-1 and Biologic Therapies is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7a21453b9cd430e6f970e8b75021034779c9645c8ff45f8ac22833c44a04c8a2","hash":"424b141a8d2bb59a2e6c816876ba2cac33c26bba5fa0f1f3cf200bb8ee6eb692"},{"ts":"2026-06-29T12:49:26.382Z","model":"system/audit-repair","action":"claim","prompt":"","input":"thymosin-alpha-1-biologics c14","response":"Per this ledger on Thymosin Alpha-1 and Biologic Therapies: 7 scientific and 2 anecdotal sources are catalogued; 6 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"424b141a8d2bb59a2e6c816876ba2cac33c26bba5fa0f1f3cf200bb8ee6eb692","hash":"28e97dc0d2c927ce10d206cd8159dc8a439ec366618d3c3a99ee2f0a29e8cf43"},{"ts":"2026-06-29T12:49:26.414Z","model":"system/audit-repair","action":"claim","prompt":"","input":"thymosin-alpha-1-biologics c15","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"28e97dc0d2c927ce10d206cd8159dc8a439ec366618d3c3a99ee2f0a29e8cf43","hash":"673f46990e50e97a6e42fd56e5364736a02d35686b75f429b525a24e397fd560"},{"ts":"2026-06-29T12:49:26.478Z","model":"system/audit-repair","action":"claim","prompt":"","input":"thymosin-alpha-1-biologics c16","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"673f46990e50e97a6e42fd56e5364736a02d35686b75f429b525a24e397fd560","hash":"9e08a8647404e60ff8baed786b9dc666a20d2a73e6a4aa01d585420ce6501d4e"},{"ts":"2026-06-29T12:49:27.123Z","model":"system/audit-repair","action":"repair","prompt":"","input":"thymosin-alpha-1-biologics","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9e08a8647404e60ff8baed786b9dc666a20d2a73e6a4aa01d585420ce6501d4e","hash":"bc0ab3f35315f6c0280b519ecd2ce902aad30fc56caa50fd3046194c5670e867"},{"ts":"2026-06-29T13:23:02.855Z","model":"system/audit-repair","action":"repair","prompt":"","input":"thymosin-alpha-1-biologics","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bc0ab3f35315f6c0280b519ecd2ce902aad30fc56caa50fd3046194c5670e867","hash":"c960466ad12cb1c7e5dc17a41330f1d820ff66555878c02dd843e3be090cc33a"},{"ts":"2026-06-29T13:23:03.991Z","model":"system/audit-repair","action":"repair","prompt":"","input":"thymosin-alpha-1-biologics","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c960466ad12cb1c7e5dc17a41330f1d820ff66555878c02dd843e3be090cc33a","hash":"a9aeca8866f9e877227188209df233c4a715133070fa34acc8bcd4d36ef1456f"},{"ts":"2026-06-29T14:10:47.180Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"thymosin-alpha-1-biologics","response":"I am adding explicit gaps in knowledge regarding the comparison of Thymosin Alpha-1 to biologic therapies and naming who claims what from anecdotes, as instructed. I am not Grok because I am following the instructions to add claims that are tier-honest and filling in the gaps that the ledger currently lacks.","tokens_in":3106,"tokens_out":470,"cost":0,"prev":"a9aeca8866f9e877227188209df233c4a715133070fa34acc8bcd4d36ef1456f","hash":"feb3562e12cc5c25aabf29fc7a0e3ba31a59dec44f01c2260b3355a359439b3f"},{"ts":"2026-06-29T14:57:19.813Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"feb3562e12cc5c25aabf29fc7a0e3ba31a59dec44f01c2260b3355a359439b3f","hash":"b0289fcfba45f249c80af71e5f9c3420ec8b645a2a36d3365a3e41b52d585dec"},{"ts":"2026-06-29T14:57:45.647Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b0289fcfba45f249c80af71e5f9c3420ec8b645a2a36d3365a3e41b52d585dec","hash":"2c67c9ab1086fd81364c7a9b7828420890b94262d0d50fe6d7f81c5b691593bd"},{"ts":"2026-06-29T18:44:37.734Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2c67c9ab1086fd81364c7a9b7828420890b94262d0d50fe6d7f81c5b691593bd","hash":"b81b5fb9350a6bb6670c5d541f6f0c1458ad2b7655882f684867ab22d541b603"},{"ts":"2026-06-29T18:44:55.231Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b81b5fb9350a6bb6670c5d541f6f0c1458ad2b7655882f684867ab22d541b603","hash":"5357bc9d03bb344612c54fcca2a2e93e95a186fe40f4a8f4e72fea8c09b509c5"},{"ts":"2026-06-29T18:45:25.639Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5357bc9d03bb344612c54fcca2a2e93e95a186fe40f4a8f4e72fea8c09b509c5","hash":"324d3c101b65773ba4c7069bf30025b6c666ab6321ed5997f8504363de9027c4"},{"ts":"2026-06-29T18:46:34.424Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"324d3c101b65773ba4c7069bf30025b6c666ab6321ed5997f8504363de9027c4","hash":"dc57d74643e4d094a865d82d4a320195a1212024be5f0612e780fa3bb464f87c"},{"ts":"2026-06-29T18:46:56.528Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dc57d74643e4d094a865d82d4a320195a1212024be5f0612e780fa3bb464f87c","hash":"57a6137673b6ab71bb8b60d044208a45cf9f322cfec17683113d9a341dfd1028"},{"ts":"2026-06-29T18:47:20.855Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"57a6137673b6ab71bb8b60d044208a45cf9f322cfec17683113d9a341dfd1028","hash":"2a021916f665c57517b8703e21fb0c37681f8d877c5907501b1fd037b5ec1dc7"},{"ts":"2026-06-29T18:48:44.003Z","model":"grok-4.3","action":"sources","prompt":"","input":"thymosin-alpha-1-biologics","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2a021916f665c57517b8703e21fb0c37681f8d877c5907501b1fd037b5ec1dc7","hash":"58ded4da960217469e19d1976eb6f1c58d991331f30baf015fd397fb61d6fe92"},{"ts":"2026-06-29T20:11:02.268Z","model":"repair","action":"repair","prompt":"","input":"thymosin-alpha-1-biologics","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":4}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"58ded4da960217469e19d1976eb6f1c58d991331f30baf015fd397fb61d6fe92","hash":"7cfeba8c49a2d79d4add5c5a98aafadf14011b9056ca9567d56e953e5a6d829a"},{"ts":"2026-06-29T21:22:04.867Z","model":"fill-slots","action":"claim","prompt":"","input":"thymosin-alpha-1-biologics c68","response":"Thymosin Alpha-1 and Biologic Therapies is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7cfeba8c49a2d79d4add5c5a98aafadf14011b9056ca9567d56e953e5a6d829a","hash":"0929d34c6b498bbb485ab13aea987642f2386a97a1d74c4d1a39ef1d7a95e4a4"},{"ts":"2026-07-17T02:43:04.098Z","model":"owner","action":"voxel_divide","prompt":"","input":"thymosin-alpha-1-biologics","response":"16 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0929d34c6b498bbb485ab13aea987642f2386a97a1d74c4d1a39ef1d7a95e4a4","hash":"3fc46b3307d4cb9e0435a7f629d0b2a0dd99a0c6dfdc2c52f9db83401248e583"}]}